Ipsen Pharma Sas
Reporting payments is a legal requirement; large totals often reflect large product portfolios.
$388Kgeneral payments (2019-2025)
$23Kresearch payments (2019-2025)
229clinicians paid
General and research payments are shown separately, never blended. Research payments are often institution-directed and tied to clinical trials.
General payments by year
General payments only, as reported to CMS. Research payments are totaled above and not included in these bars.
Products most associated with its payments
Specialties it works with most
Clinicians with the largest reported totals
Often long-running consulting, speaking, or advisory relationships, which companies must report by law. A large total is not evidence of anything improper.
| Clinician | Location | Specialty | General payments (2019-2025) |
|---|---|---|---|
| Atul Patel | Overland Park, KS | Physical Medicine & Rehabilitation | $40,641.76 |
| Mark Nestor | Aventura, FL | Dermatology | $30,009.31 |
| Alberto Esquenazi | Philadelphia, PA | Physical Medicine & Rehabilitation | $22,118.05 |
| Chaitanya Divgi | New York, NY | Nuclear Medicine | $20,335.00 |
| Richard Zorowitz | Washington, DC | Physical Medicine & Rehabilitation | $17,025.04 |
| Nizar Tannir | Houston, TX | Medical Oncology | $14,537.25 |
| Sumanta Pal | Duarte, CA | Medical Oncology | $13,872.76 |
| Douglas Orr | Dallas, TX | Medical Oncology | $12,769.21 |
| Eric Jonasch | Houston, TX | Medical Oncology | $12,167.50 |
| Lee Chung | Salt Lake City, UT | Vascular Neurology | $11,908.13 |
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.